drugset

drugset / Trial / NCT00677339

L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)

NCT00677339 ↗

Phase 3 Completed 200 enrolled Menzies School of Health Research Australian National University · collab National Institute of Health Research and Development, Ministry of Health Republic of Indonesia · collab

RandomizedFactorialQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether adjunctive L-arginine and vitamin D can improve response to standard short course TB therapy in people with newly diagnosed pulmonary TB.

Timeline

Start: 2008-06
Primary completion: 2010-02
Completion: 2010-05

Publications

Ralph AP, Waramori G, Pontororing GJ, Kenangalem E, Wiguna A, Tjitra E, Sandjaja, Lolong DB, Yeo TW, Chatfield MD, Soemanto RK, Bastian I, Lumb R, Maguire GP, Eisman J, Price RN, Morris PS, Kelly PM, Anstey NM. L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS One. 2013 Aug 14;8(8):e70032. doi: 10.1371/journal.pone.0070032. eCollection 2013.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Cholecalciferol	Other / unclassified	50000 iu	Oral
Comparator	L-arginine	Small molecule	6 g	Oral

Indications